1
2
Kirshner, Ghyli, Makai, Peter, Brouns, Chiara, Timmers, Lonneke, Kemp, Ron
Veröffentlicht in: Kirshner , G , Makai , P , Brouns , C , Timmers , L & Kemp , R 2024 , ' The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs : a case study on the introduction of a second administration form of trastuzumab in The Netherlands ' , European Journal of Health Economics . https://doi.org/10.1007/s10198-023-01648-w;
2024
Veröffentlicht in: Kirshner , G , Makai , P , Brouns , C , Timmers , L & Kemp , R 2024 , ' The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs : a case study on the introduction of a second administration form of trastuzumab in The Netherlands ' , European Journal of Health Economics . https://doi.org/10.1007/s10198-023-01648-w;
2024
3
Kirshner, Ghyli, Makai, Peter, Brouns, Chiara, Timmers, Lonneke, Kemp, Ron
Veröffentlicht in: The European Journal of Health Economics ; ISSN 1618-7598 1618-7601;
2024
Veröffentlicht in: The European Journal of Health Economics ; ISSN 1618-7598 1618-7601;
2024
4
5
6